Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1009, USA.
Anesthesiology. 2010 May;112(5):1225-33. doi: 10.1097/ALN.0b013e3181d94dc0.
Nonsteroidal antiinflammatory drugs are commonly used to treat postoperative and chronic pain. Animal studies suggest that these drugs act, in part, by blocking prostaglandin production in the spinal cord. The authors tested intrathecal ketorolac in patients with chronic or postoperative pain.
After approval of the institutional review board and the Food and Drug Administration, three clinical studies were performed. First, 15 patients receiving chronic intrathecal morphine received 0.5-2.0 mg of intrathecal ketorolac. Second, 12 patients receiving chronic intrathecal morphine received, in a double-blinded, randomized, cross-over design, intrathecal saline or 2.0 mg of ketorolac, with pain intensity as the primary outcome measure. Third, 30 patients undergoing total vaginal hysterectomy received, in a double-blinded, randomized, controlled design, intrathecal saline or 2.0 mg of ketorolac, with bupivacaine with time to first morphine dose after surgery as the primary outcome measure.
Patients with chronic pain had many symptoms before intrathecal injection, without worsening of these symptoms from ketorolac. Pain intensity was reduced by intrathecal ketorolac, but this did not differ from placebo. In the first study, pain was reduced by intrathecal ketorolac in patients with high cerebrospinal fluid prostaglandin E2 concentrations but not in those with normal concentrations. Intrathecal ketorolac did not alter time to first morphine after surgery.
Intrathecal ketorolac did not relieve chronic pain or extend anesthesia or analgesia from intrathecal bupivacaine administered at the beginning of surgery. Under the conditions of these studies, it seems that spinal cylcooxygenase activity does not contribute to chronic or postoperative pain.
非甾体类抗炎药常用于治疗术后和慢性疼痛。动物研究表明,这些药物的作用部分是通过阻断脊髓中的前列腺素生成。作者在慢性或术后疼痛患者中测试了鞘内注射酮咯酸。
在机构审查委员会和食品药品监督管理局批准后,进行了三项临床研究。首先,15 名接受慢性鞘内吗啡治疗的患者接受了 0.5-2.0mg 的鞘内酮咯酸。其次,12 名接受慢性鞘内吗啡治疗的患者采用双盲、随机、交叉设计接受鞘内生理盐水或 2.0mg 酮咯酸治疗,以疼痛强度为主要观察指标。第三,30 例行全阴道子宫切除术的患者采用双盲、随机、对照设计接受鞘内生理盐水或 2.0mg 酮咯酸治疗,以布比卡因术后首次吗啡剂量时间为主要观察指标。
慢性疼痛患者在鞘内注射前有许多症状,鞘内注射酮咯酸并未加重这些症状。鞘内注射酮咯酸可减轻疼痛,但与安慰剂无差异。在第一项研究中,鞘内注射酮咯酸可减轻高脑脊液前列腺素 E2 浓度患者的疼痛,但不能减轻正常浓度患者的疼痛。鞘内注射酮咯酸并未改变术后首次吗啡时间。
鞘内注射酮咯酸不能缓解慢性疼痛,也不能延长手术开始时鞘内布比卡因的麻醉和镇痛时间。在这些研究条件下,脊髓环氧化酶活性似乎与慢性或术后疼痛无关。